India seeks new preferential treatment from US on drugs, other goods

India accounts for 40 per cent of US generic drug imports, including the anti-malarial hydroxychloroquine, touted by US President Donald Trump in the fight against Covid-19.

drug, medicine, drugs, pharma, pharmaceutical
To win preferential treatment on pharmaceutical exports, the government of Prime Minister Narendra Modi is dangling the carrot of opening its dairy and farm markets to the Trump administration
Reuters New Delhi
2 min read Last Updated : Jul 21 2020 | 1:00 AM IST
India is seeking concessions for generic drugs it exports to the US in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal, three sources said.

India accounts for 40 per cent of US generic drug imports, including the anti-malarial hydroxychloroquine, touted by US President Donald Trump in the fight against Covid-19.

To win preferential treatment on pharmaceutical exports, the government of Prime Minister Narendra Modi is dangling the carrot of opening its dairy and farm markets to the Trump administration, months ahead of the US presidential election.

“Americans recognise the political compulsion that brings its own benefits,” one of the sources with knowledge of the plans said.

India, one of the world’s largest consumers of dairy products, has offered an opening to US dairy imports through a quota-based system, two of the sources said. These products would need a certificate they are not derived from animals that have consumed feeds that include internal organs, blood meal or tissues of ruminants because of religious sensibilities in India.

India's federal trade ministry did not immediately comment and the US Embassy in New Delhi referred questions to the US Trade Representative.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusHydroxychloroquineIndian pharma companiesdrug exportDonald Trumpgeneric drugs

Next Story